Bit disappointing to see a revised Announcement, but nonetheless the crux of the partnership has not changed.
Also, it's not surprising to see a tie-up with a Japanese pharmaceutical - there's a lot of exosome research coming out of Japan, South Korea and China. If I had to guess, our next partnership will be with another group headquartered in Japan, South Korea or China. Potentially Exopharm is focused on 'monopolising' the Asia region before Lonza/Codiak can make their move.
Bit disappointing to see a revised Announcement, but nonetheless...
Add TYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $20.69M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 2.0¢ | 1.9¢ | $4.215K | 219.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 2259021 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 71951 | 2 |
View Market Depth
| Last trade - 12.26pm 18/06/2024 (20 minute delay) ? |
|
|||||
|
Last
1.9¢ |
Change
0.000 ( 5.00 %) |
||||
| Open | High | Low | Volume | ||
| 1.9¢ | 1.9¢ | 1.9¢ | 39311 | ||
| Last updated 10.28am 18/06/2024 ? | |||||
| TYP (ASX) Chart |